DK2922846T3 - Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha - Google Patents
Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha Download PDFInfo
- Publication number
- DK2922846T3 DK2922846T3 DK13811640.5T DK13811640T DK2922846T3 DK 2922846 T3 DK2922846 T3 DK 2922846T3 DK 13811640 T DK13811640 T DK 13811640T DK 2922846 T3 DK2922846 T3 DK 2922846T3
- Authority
- DK
- Denmark
- Prior art keywords
- substituted
- mmol
- occurrence
- alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
- AMID-SUBSTITUEREDE HETEROCYKLISKE FORBINDELSER, DER ER ANVENDELIGE SOM MODULATORER AF IL-12, IL-23 OG/ELLER IFN-ALPHA1. Forbindelse med følgende formel I:eller et farmaceutisk acceptabelt salt deraf, hvor: Y er CR6; R1 er valgt fra H og C^-alkyl eller C3.6-cycloalkyl, der hver eventuelt er substitueret med 0-7 Rla; Rla ved hver forekomst uafhængigt er hydrogen, deuterium, F, Cl, Br eller CN; R2 er:R3 er C340 -cycloalkyl, eller C6.10_aryl, hvor hver gruppe er substitueret med 0-4 R3a; R3a ved hver forekomst uafhængigt er hydrogen, =O, halo, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CHAQCONR1^11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRhCiO)NR" R11. -S(O)pNR11R11, -NRbS(O)pRc, -S(O)pRc, C μ,,-alkyl substitueret med 0-3 Ra, C2.6-alkenyl substitueret med 0-3 Ra, C2.6-alkynyl substitueret med 0-3 Ra, C^-haloalkyl, -(CH2)r-3-14-leddet carbocyklus substitueret med 0-3 Ra eller en -(CH2)r-5-10-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O og S(O)p substitueret med 0-3 Ra; eller to R3a, sammen med de atomer, hvortil de er bundet, kombineres for at danne en kondenseret ring, hvor ringen er valgt fra phenyl og en heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O og S(O)p, hver kondenseret ring substitueret med 0-3 Ral; R4 og R5 uafhængigt er hydrogen, Ci_4-alkyl substitueret med 0-1 Rf, (CH2)r.phenyl substitueret med 0-3 Rd eller en -(CH2)-5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O, og S(O)p; R6 er hydrogen, halo, Ci^-alkyl, C1.4-haloalkyl, OCi^-haloalkyl, OCi^-alkyl, CN, NO2 eller OH;R11 ved hver forekomst er uafhængigt hydrogen, C1.4-alkyl substitueret med 0-3 Rf, CF3, C3.lo-cycloalkyl substitueret med 0-1 Rf, (CH)r-phenyl substitueret med 0-3 Rd eller -(CH2)r-5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O og S(O)p substitueret med 0-3 Rd; Ra og Ral ved hver forekomst uafhængigt er hydrogen, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CH2)rC(O)ORb, -(CH2)rOC(O)Rb, -(CH2)rNR11R11, - (CiLXCONR1^11, -(CH2)rNRbC(O)Rc, -(CH2)rNRbC(O)ORc, -NRhC(O)NR" R11. -SfO^NR1^11, -NRbS(O)pRc, -S(O)RC, -S(O)2Rc, Ci_6-alkyl substitueret med 0-3 Rf, Ci_6-haloalkyl, C2_6-alkenyl substitueret med 0-3 Ra, C2_6-alkynyl substitueret med 0-3 Ra, -(CH2)r-3-14-leddet carbocyklus eller -(CH2)r.5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O, og S(O)p substitueret med 0-3 Rf; Rb er hydrogen, Ci_6-alkyl substitueret med 0-3 Rd, Ci_6-haloalkyl, C3_6-cycloalkyl substitueret med 0-2 Rd, eller -(CH2)r-5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O og S(O)p substitueret med 0-3 Rf eller (CH2)r-phenyl substitueret med 0-3 Rd; Rc er Ci_6-alkyl substitueret med 0-3 Rf, (CH2)r-C3_6-cycloalkyl substitueret med 0-3 Rf eller (CH2)r-phenyl substitueret med 0-3 Rf; Rd ved hver forekomst uafhængigt er hydrogen, F, Cl, Br, OCF3, CF3, CN, NO2, -ORe, -(CH2)rC(O)Rc, -NReRe, -NReC(O)ORc, C1.6-alkyl eller (CH2)r-phenyl substitueret med 0-3 Rf; Re ved hver forekomst uafhængigt er valgt fra hydrogen, Ci_6-alkyl, C3.6-cycloalkyl og (CH2)r-phenyl substitueret med 0-3 Rf; Rf uafhængigt ved hver forekomst er hydrogen, halo, CN, NH2, OH, C3_6-cycloalkyl, CF3, O(Ci-e-alkyl) eller en -(CH2)r-5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O og S(O)p; p er 0, 1 eller 2; og r er 0, 1, 2, 3 eller 4.
- 2. Forbindelse ifølge krav 1, eller et farmaceutisk acceptabelt salt deraf, hvor både R4 og R5 er hydrogen.
- 3. Forbindelse ifølge et hvilket som helst af kravene 1-2 med følgende formel:eller et farmaceutisk acceptabelt salt deraf, hvor: R1 er H eller C^-alkyl substitueret med 0-7 Rla; Rla ved hver forekomst uafhængigt er hydrogen, deuterium eller halogen; R3 er C3.io -cycloalkyl, eller en C6.10-aryl, hvor hver gruppe er substitueret med 0-4 R3a; R3a ved hver forekomst uafhængigt er hydrogen, halo, OCF3, CF3, CHF2, CN, -(CH2)rORb, -(CH2)rSRb, -(CH2)rC(O)Rb, -(CHzXNR1^11, -(CH2)rC(O)NR11R11, -(CH2)rNRbC(O)Rc, -SfCOpNR1^11, -NRbS(O)pRc, -S(O)pRc, C1.6-alkyl substitueret med 0-3 Ra, C1.6-haloalkyl, en -(CH2)r-3-14-leddetcarbocyklus substitueret med 0-3 Ra eller en -(CH2)r-5-10-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O og S(O)p substitueret med 0-3 Ra; eller to R3a, sammen med de atomer, hvortil de er bundet, kombineres for at danne en kondenseret ring, hvor denne ring er valgt fra phenyl og en 5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, S eller O, hvor hver kondenseret ring er substitueret, når valens tillader det, med 0-3 Ra; R11 ved hver forekomst uafhængigt er hydrogen, C^-alkyl substitueret med 0-3 Rf eller C3_ 6cycloalkyl substitueret med 0-1 Rf; Ra ved hver forekomst er hydrogen, =O, F, -(CH2)rORb eller C^-alkyl substitueret med 0-3 Rf; Rb er hydrogen, C|_,,-alkyl substitueret med 0-3 Rd, G -haloalkyl. C3.6-cycloalkyl substitueret med 0-2 Rd, eller -(CH2)r-5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, O og S(O)p substitueret med 0-3 Rf; eller (CH2)r-phenyl substitueret med 0-3 Rd; Rc er substitueret Ci_6-alkyl eller C3_6-cycloalkyl, hvor hver gruppe er substitueret med 0-3 Rf; Rd ved hver forekomst uafhængigt er hydrogen, F, Cl, Br eller -OH; Rf ved hver forekomst uafhængigt er hydrogen, halo, CN, OH eller O(Cr6-alkyl); p er 0, 1 eller 2; og r er 0, 1 eller 2.
- 4. Forbindelse ifølge et hvilket som helst af kravene 1-3, eller et farmaceutisk acceptabelt salt deraf, hvor R3 er phenyl, cyclopentyl, eller cyclohexyl, hvor hver gruppe er substitueret med 0-4 R3a.
- 5. Forbindelse ifølge et hvilket som helst af kravene 1-4, eller et farmaceutisk acceptabelt salt deraf, hvor: R3a ved hver forekomst uafhængigt er hydrogen, Ph, CN, NH2, OCF3, ORb, halo, cycloalkyl, C(O)NR11R11, S(O)2NRnRn, C(O)Rb, SOpRc, NRbSOpRc, NRbC(O)Rc, haloalkyl, CN, 5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, S eller O substitueret med 0-3 Ra og Ci_6-alkyl substitueret med 0-3 Ra; eller én R3a og en anden R3a, sammen med de atomer, hvortil de er bundet, kombineres for at danne en kondenseret 5-7-leddet heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, S eller O eller phenyl; R11 ved hver forekomst uafhængigt er hydrogen, C3.6-cycloalkyl substitueret med 0-3 Rf, eller Q. 4alkyl substitueret med 0-1 Rf; Ra uafhængigt ved hver forekomst er C|.,,-alkyl substitueret med 0-3 Rf, halo eller ORb; Rb uafhængigt ved hver forekomst er hydrogen, 5-7-leddet-heterocyklus, der indeholder 1-4 heteroatomer valgt fra N, S eller O substitueret med 0-3 Rf, eller Ci_6-alkyl substitueret med 0-3 Rd; Rd uafhængigt ved hver forekomst er F, Cl, Br eller OH; Rc uafhængigt ved hver forekomst er Ci_6-alkyl eller C3_6-cycloalkyl, hvor hver gruppe er substitueret med 0-3 Rf; Rf uafhængigt ved hver forekomst er hydrogen, halo eller OH; og p er 2.
- 6. Forbindelse ifølge et hvilket som helst af kravene 1-5, eller et farmaceutisk acceptabelt salt deraf, hvor: R3 erR3aa er S(O)pRc, ORb, chlor, F, CN, NH2, C(O)NR11R11, NRbSOpRc, NRbC(O)Rc, C^-alkyl substitueret med 0-3 Ra eller en 5- til 6-leddet heteroaryl, der indeholder 1-3 heteroatomer valgt fra N, O og S substitueret med 0-3 R3a; R3ab, R3ac eller R3ad uafhængigt er hydrogen, Cl, F, Br, CN, ORb, , _6-alkyl substitueret 0-3 Ra; C(O)NR11R11, C(O)Rb, S(O)pRc, eller en 4-7-leddet heterocyklus, der indeholder 1-3 heteroatomer valgt fra N, O og S substitueret med 0-3 Ra; R11 ved hver forekomst uafhængigt er hydrogen, cyclopropyl substitueret med 0-3 Rf eller Ci^-alkyl substitueret med 0-3 Rf; Ra ved hver forekomst uafhængigt er C -alkyl substitueret med 0-3 Rf, ORb eller halo; Rb ved hver forekomst uafhængigt er hydrogen, ( ' i _f,-alkyl substitueret med 0-2 Rd eller en 5- til 7-leddet heterocyklus, der indeholder 1-3 heteroatomer valgt fra N, O og S; Rc ved hver forekomst uafhængigt er C -alkyl substitueret med 0-3 Rf; Rd ved hver forekomst uafhængigt er F eller OH; Rf ved hver forekomst uafhængigt er halo eller OH; og p er 0-2.
- 7. Forbindelse ifølge krav 6, eller et farmaceutisk acceptabelt salt deraf, hvor R3aa er S(O)pRc eller C(O)NR11R11.
- 8. Forbindelse ifølge krav 6, eller et farmaceutisk acceptabelt salt deraf, hvor R3aa er ORb.
- 9. Forbindelse ifølge et hvilket som helst af kravene 1-8, eller et farmaceutisk acceptabelt salt deraf, hvor R3 er:
- 10. Forbindelse ifølge krav 1, der er
- 11. Forbindelse ifølge krav 1, der er et farmaceutisk acceptabelt salt of:
- 12. Farmaceutisk sammensætning, der omfatter én eller flere forbindelser ifølge et hvilket som helst af kravene 1-11 og en farmaceutisk acceptabel bærer eller diluent.
- 13. Forbindelse ifølge et hvilket som helst af kravene 1-11 til anvendelse i behandling af en inflammatorisk eller autoimmun sygdom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723840P | 2012-11-08 | 2012-11-08 | |
PCT/US2013/068846 WO2014074661A1 (en) | 2012-11-08 | 2013-11-07 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2922846T3 true DK2922846T3 (da) | 2019-01-21 |
Family
ID=49876960
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18197550.9T DK3495358T3 (da) | 2012-11-08 | 2013-11-07 | Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha-reaktioner |
DK13811640.5T DK2922846T3 (da) | 2012-11-08 | 2013-11-07 | Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18197550.9T DK3495358T3 (da) | 2012-11-08 | 2013-11-07 | Amid-substituerede heterocykliske forbindelser, der er anvendelige som modulatorer af il-12, il-23 og/eller ifn-alpha-reaktioner |
Country Status (38)
Country | Link |
---|---|
US (6) | US9505748B2 (da) |
EP (3) | EP2922846B1 (da) |
JP (3) | JP6407159B2 (da) |
KR (1) | KR102195194B1 (da) |
CN (1) | CN104884454B (da) |
AR (1) | AR094452A1 (da) |
AU (4) | AU2013341186B2 (da) |
BR (1) | BR112015010102B1 (da) |
CA (1) | CA2890981C (da) |
CL (1) | CL2015001231A1 (da) |
CY (2) | CY1121188T1 (da) |
DK (2) | DK3495358T3 (da) |
EA (1) | EA028814B1 (da) |
ES (2) | ES2914793T3 (da) |
FI (1) | FIC20230028I1 (da) |
FR (1) | FR23C1030I1 (da) |
HK (1) | HK1215255A1 (da) |
HR (2) | HRP20220766T1 (da) |
HU (3) | HUE059409T2 (da) |
IL (1) | IL238610A0 (da) |
LT (3) | LT2922846T (da) |
MA (1) | MA38072A1 (da) |
MX (2) | MX2015005731A (da) |
MY (2) | MY194668A (da) |
NL (1) | NL301238I2 (da) |
NZ (1) | NZ708859A (da) |
PE (1) | PE20150944A1 (da) |
PH (1) | PH12015501004A1 (da) |
PL (2) | PL3495358T3 (da) |
PT (2) | PT3495358T (da) |
RS (2) | RS63328B1 (da) |
SG (3) | SG11201503399XA (da) |
SI (2) | SI3495358T1 (da) |
TR (1) | TR201820824T4 (da) |
TW (1) | TWI605041B (da) |
UY (1) | UY35126A (da) |
WO (1) | WO2014074661A1 (da) |
ZA (1) | ZA201504052B (da) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2914793T3 (es) * | 2012-11-08 | 2022-06-16 | Bristol Myers Squibb Co | Compuestos heterocíclicos sustituidos con amida, útiles como moduladores de la respuesta de IL-12, IL-23 y/o IFN-alfa |
SG11201503395TA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物 |
ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
US9834548B2 (en) | 2014-02-14 | 2017-12-05 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as JAK inhibitors |
PT3380465T (pt) * | 2015-11-26 | 2020-10-23 | Novartis Ag | Derivados de diamino piridina |
JP7082130B2 (ja) | 2016-10-14 | 2022-06-07 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用 |
US10647713B2 (en) | 2016-10-21 | 2020-05-12 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
EP3555111B1 (en) | 2016-12-13 | 2022-01-26 | Bristol-Myers Squibb Company | Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
US10336752B2 (en) | 2017-03-08 | 2019-07-02 | Nimbus Lakshmi, Inc. | TYK2 inhibitors, uses, and methods for production thereof |
US10899745B2 (en) | 2017-03-30 | 2021-01-26 | Bristol-Myers Squibb Company | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide |
EA202091269A1 (ru) * | 2017-11-21 | 2020-08-07 | Бристол-Маерс Сквибб Компани | Сульфон-, пиридин-, алкил-, амид-замещенные гетероарильные соединения |
JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ2媒介性シグナル伝達の阻害剤 |
ES2944733T3 (es) * | 2018-03-22 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos heterocíclicos que comprenden piridina, útiles como moduladores de las respuestas a IL-12, IL-23 y/o IFN alfa |
US11613529B2 (en) | 2018-05-31 | 2023-03-28 | Bristol-Myers Squibb Company | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3) pyridazine-3-carboxamide |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
WO2020081508A1 (en) | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
WO2020086616A1 (en) | 2018-10-22 | 2020-04-30 | Fronthera U.S. Pharmaceuticals Llc | Tyk2 inhibitors and uses thereof |
AU2019373203A1 (en) * | 2018-10-30 | 2021-06-10 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
AU2019389025A1 (en) | 2018-11-30 | 2021-06-17 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
CA3126034A1 (en) | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
JP2022524279A (ja) * | 2019-01-28 | 2022-05-02 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ピリダジン系誘導体阻害剤、その製造方法及び使用 |
CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
CA3128014A1 (en) * | 2019-01-30 | 2020-08-06 | Bristol-Myers Squibb Company | Amide-disubstituted pyridine or pyridazine compounds |
MX2021013317A (es) | 2019-04-30 | 2022-01-18 | Celgene Corp | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. |
US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
JP2022536489A (ja) | 2019-06-12 | 2022-08-17 | ブリストル-マイヤーズ スクイブ カンパニー | 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶性塩形態 |
US20230167082A1 (en) * | 2019-07-16 | 2023-06-01 | Bristol-Myers Squibb Company | Prodrugs in the modulation of interleukin |
EP4007757A4 (en) * | 2019-08-01 | 2023-07-19 | Integral Biosciences Pvt. Ltd. | HETEROCYCLIC COMPOUND AS KINASE INHIBITORS AND USES THEREOF |
WO2021050964A1 (en) | 2019-09-13 | 2021-03-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
BR112022004550A2 (pt) * | 2019-09-18 | 2022-05-31 | Bristol Myers Squibb Co | Formas de dosagem para inibidores de tyk2 |
WO2021129467A1 (zh) * | 2019-12-27 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种bms-986165晶型及其制备方法和用途 |
WO2021143430A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型及其制备方法和用途 |
WO2021143498A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
US20230159520A1 (en) * | 2020-02-26 | 2023-05-25 | Beigene, Ltd. | Tyk-2 inhibitor |
BR112022017440A2 (pt) * | 2020-03-11 | 2022-10-18 | Beijing Innocare Pharma Tech Co Ltd | Compostos heterocíclicos para inibir atividades de tyk2 |
WO2021204626A1 (en) * | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
CN113563309A (zh) * | 2020-04-28 | 2021-10-29 | 浙江海正药业股份有限公司 | 吡啶类衍生物及其制备方法和用途 |
WO2021222153A1 (en) * | 2020-04-28 | 2021-11-04 | Bristol-Myers Squibb Company | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators |
CN113735836B (zh) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | 哒嗪类化合物及其应用 |
CN113735837B (zh) * | 2020-05-28 | 2023-09-01 | 江苏先声药业有限公司 | 哒嗪类化合物及其用途 |
CN113773262A (zh) * | 2020-06-09 | 2021-12-10 | 江苏先声药业有限公司 | 哒嗪类化合物 |
CN115667246A (zh) * | 2020-07-24 | 2023-01-31 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 |
EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
WO2022021684A1 (zh) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型csv及其制备方法和用途 |
CA3192982A1 (en) | 2020-09-18 | 2022-03-24 | Umesh KESTUR | Dosage forms for tyk2 inhibitors comprising swellable cores |
WO2022083649A1 (zh) * | 2020-10-20 | 2022-04-28 | 杭州领业医药科技有限公司 | 哒嗪衍生物的晶型 |
CN116490501A (zh) * | 2020-11-12 | 2023-07-25 | 上海睿跃生物科技有限公司 | 酪氨酸激酶2(tyk2)降解化合物和使用方法 |
TW202227430A (zh) * | 2020-11-17 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
CN116547276A (zh) * | 2020-12-08 | 2023-08-04 | 正大天晴药业集团股份有限公司 | 含酰胺基和杂环烷基的tyk2抑制剂化合物 |
WO2022165141A1 (en) | 2021-01-29 | 2022-08-04 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
US20230091528A1 (en) | 2021-02-02 | 2023-03-23 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
AU2022216810A1 (en) | 2021-02-02 | 2023-08-24 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的tyk2抑制劑化合物、藥物組合物及其用途 |
JP2024508794A (ja) | 2021-02-19 | 2024-02-28 | スドー バイオサイエンシーズ リミテッド | Tyk2阻害剤およびその使用 |
WO2022187856A1 (en) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
JP2024510274A (ja) * | 2021-03-16 | 2024-03-06 | アンルイ バイオメディカル テクノロジー (グァンヂョウ) カンパニー リミテッド | アミノヘテロアリール化合物および組成物 |
WO2022212181A1 (en) | 2021-03-29 | 2022-10-06 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
US20240182429A1 (en) * | 2021-03-30 | 2024-06-06 | Zhejiang Wenda Pharma Technology Ltd. | Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use |
CN115197196B (zh) * | 2021-04-06 | 2024-06-18 | 扬子江药业集团有限公司 | Tyk2抑制剂及其用途 |
AU2022268464A1 (en) | 2021-05-04 | 2023-12-21 | Shanghai Zheye Biotechnology Co. Ltd. | Nitrogen-containing heterocyclic pyridine compound |
WO2022241173A1 (en) | 2021-05-14 | 2022-11-17 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
WO2022241175A1 (en) | 2021-05-14 | 2022-11-17 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
JP2024518556A (ja) | 2021-05-14 | 2024-05-01 | ブリストル-マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
MX2023013445A (es) | 2021-05-14 | 2023-12-14 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos. |
WO2022253335A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 含磺酰基的芳基类化合物及其应用 |
WO2022268119A1 (zh) * | 2021-06-22 | 2022-12-29 | 南京明德新药研发有限公司 | 亚磺酰亚胺类化合物及其应用 |
CN117794911A (zh) * | 2021-07-15 | 2024-03-29 | 南京明德新药研发有限公司 | 含硫/磷的芳基类化合物及其应用 |
EP4387968A1 (en) * | 2021-08-20 | 2024-06-26 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
TW202313035A (zh) * | 2021-08-21 | 2023-04-01 | 美商傳達治療有限公司 | Jak2抑制劑及其使用方法 |
AU2022350509A1 (en) | 2021-09-23 | 2024-04-04 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
WO2023055901A2 (en) | 2021-09-30 | 2023-04-06 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
IL312330A (en) | 2021-10-25 | 2024-06-01 | Kymera Therapeutics Inc | TYK2 joints and their uses |
WO2023076515A1 (en) | 2021-10-28 | 2023-05-04 | Bristol-Myers Squibb Company | Topical formulations of deucravacitinib |
WO2023102085A1 (en) | 2021-12-01 | 2023-06-08 | Teva Czech Industries S.R.O. | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
CA3240888A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
CN116693449A (zh) * | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
WO2023231997A1 (zh) * | 2022-05-31 | 2023-12-07 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
WO2024020221A1 (en) | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
WO2024028363A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
WO2024102683A1 (en) | 2022-11-08 | 2024-05-16 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
WO2024127363A1 (en) | 2022-12-16 | 2024-06-20 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
CN116284040B (zh) * | 2023-01-05 | 2024-05-28 | 华润医药研究院(深圳)有限公司 | 含氮杂环类化合物及其医药用途 |
CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797706B1 (en) | 1999-06-09 | 2004-09-28 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclecarboxamide derivative |
JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
AU5108000A (en) * | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
EA011686B1 (ru) | 2002-07-15 | 2009-04-28 | Уайт | Способ модуляции развития и функций т-клеток-хелперов |
US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
WO2011113802A2 (en) * | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
WO2012035039A1 (en) | 2010-09-15 | 2012-03-22 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
CN103313987A (zh) | 2010-11-19 | 2013-09-18 | 弗·哈夫曼-拉罗切有限公司 | 吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途 |
JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | 1,2,4−トリアジン−6−カルボキサミド誘導体 |
KR20140108594A (ko) * | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도 |
US20130310387A1 (en) * | 2012-05-16 | 2013-11-21 | Novartis Ag | Monocyclic Heteroaryl Cycloalkyldiamine Derivatives |
US9040530B2 (en) | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
EP2909174A1 (en) * | 2012-10-19 | 2015-08-26 | F. Hoffmann-La Roche AG | Inhibitors of syk |
ES2914793T3 (es) * | 2012-11-08 | 2022-06-16 | Bristol Myers Squibb Co | Compuestos heterocíclicos sustituidos con amida, útiles como moduladores de la respuesta de IL-12, IL-23 y/o IFN-alfa |
MX2015005272A (es) | 2012-11-08 | 2015-07-14 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa). |
SG11201503395TA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物 |
US10899745B2 (en) | 2017-03-30 | 2021-01-26 | Bristol-Myers Squibb Company | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide |
-
2013
- 2013-11-07 ES ES18197550T patent/ES2914793T3/es active Active
- 2013-11-07 HU HUE18197550A patent/HUE059409T2/hu unknown
- 2013-11-07 BR BR112015010102-0A patent/BR112015010102B1/pt active IP Right Grant
- 2013-11-07 MA MA38072A patent/MA38072A1/fr unknown
- 2013-11-07 RS RS20220589A patent/RS63328B1/sr unknown
- 2013-11-07 LT LTEP13811640.5T patent/LT2922846T/lt unknown
- 2013-11-07 EA EA201590917A patent/EA028814B1/ru not_active IP Right Cessation
- 2013-11-07 TR TR2018/20824T patent/TR201820824T4/tr unknown
- 2013-11-07 PT PT181975509T patent/PT3495358T/pt unknown
- 2013-11-07 AU AU2013341186A patent/AU2013341186B2/en active Active
- 2013-11-07 EP EP13811640.5A patent/EP2922846B1/en active Active
- 2013-11-07 PL PL18197550T patent/PL3495358T3/pl unknown
- 2013-11-07 CN CN201380069692.9A patent/CN104884454B/zh active Active
- 2013-11-07 ES ES13811640T patent/ES2702148T3/es active Active
- 2013-11-07 SI SI201331986T patent/SI3495358T1/sl unknown
- 2013-11-07 US US14/441,183 patent/US9505748B2/en not_active Ceased
- 2013-11-07 EP EP18197550.9A patent/EP3495358B8/en active Active
- 2013-11-07 UY UY0001035126A patent/UY35126A/es unknown
- 2013-11-07 DK DK18197550.9T patent/DK3495358T3/da active
- 2013-11-07 SG SG11201503399XA patent/SG11201503399XA/en unknown
- 2013-11-07 PL PL13811640T patent/PL2922846T3/pl unknown
- 2013-11-07 AR ARP130104091A patent/AR094452A1/es active IP Right Grant
- 2013-11-07 PT PT13811640T patent/PT2922846T/pt unknown
- 2013-11-07 RS RS20181428A patent/RS58187B1/sr unknown
- 2013-11-07 SG SG10201706985UA patent/SG10201706985UA/en unknown
- 2013-11-07 HU HUE13811640A patent/HUE041750T2/hu unknown
- 2013-11-07 KR KR1020157014694A patent/KR102195194B1/ko active IP Right Grant
- 2013-11-07 MX MX2015005731A patent/MX2015005731A/es active IP Right Grant
- 2013-11-07 MY MYPI2020005025A patent/MY194668A/en unknown
- 2013-11-07 PE PE2015000607A patent/PE20150944A1/es active IP Right Grant
- 2013-11-07 WO PCT/US2013/068846 patent/WO2014074661A1/en active Application Filing
- 2013-11-07 US US16/201,653 patent/USRE47929E1/en active Active
- 2013-11-07 CA CA2890981A patent/CA2890981C/en active Active
- 2013-11-07 EP EP22165094.8A patent/EP4071144A1/en active Pending
- 2013-11-07 LT LTEP18197550.9T patent/LT3495358T/lt unknown
- 2013-11-07 DK DK13811640.5T patent/DK2922846T3/da active
- 2013-11-07 HR HRP20220766TT patent/HRP20220766T1/hr unknown
- 2013-11-07 SI SI201331219T patent/SI2922846T1/sl unknown
- 2013-11-07 SG SG10201706897TA patent/SG10201706897TA/en unknown
- 2013-11-07 TW TW102140572A patent/TWI605041B/zh active
- 2013-11-07 NZ NZ708859A patent/NZ708859A/en unknown
- 2013-11-07 JP JP2015541883A patent/JP6407159B2/ja active Active
- 2013-11-07 MY MYPI2015701475A patent/MY175448A/en unknown
-
2015
- 2015-05-04 IL IL238610A patent/IL238610A0/en active IP Right Grant
- 2015-05-06 MX MX2020003156A patent/MX2020003156A/es unknown
- 2015-05-06 PH PH12015501004A patent/PH12015501004A1/en unknown
- 2015-05-07 CL CL2015001231A patent/CL2015001231A1/es unknown
- 2015-06-05 ZA ZA2015/04052A patent/ZA201504052B/en unknown
-
2016
- 2016-03-21 HK HK16103247.7A patent/HK1215255A1/zh unknown
- 2016-10-10 US US15/289,437 patent/US10000480B2/en active Active
-
2017
- 2017-02-17 AU AU2017201076A patent/AU2017201076B2/en active Active
-
2018
- 2018-05-15 US US15/979,770 patent/US10526321B2/en active Active
- 2018-05-16 JP JP2018094837A patent/JP6585231B2/ja active Active
- 2018-11-19 AU AU2018267545A patent/AU2018267545B2/en active Active
- 2018-11-21 HR HRP20181937TT patent/HRP20181937T1/hr unknown
- 2018-12-14 CY CY20181101343T patent/CY1121188T1/el unknown
-
2019
- 2019-09-04 JP JP2019161215A patent/JP2020002157A/ja active Pending
- 2019-11-18 US US16/687,279 patent/US11021475B2/en active Active
-
2020
- 2020-06-15 AU AU2020203967A patent/AU2020203967B2/en active Active
-
2021
- 2021-04-29 US US17/244,938 patent/US20220356180A1/en active Pending
-
2023
- 2023-07-24 NL NL301238C patent/NL301238I2/nl unknown
- 2023-07-27 CY CY2023017C patent/CY2023017I2/el unknown
- 2023-08-10 HU HUS2300025C patent/HUS2300025I1/hu unknown
- 2023-08-14 FR FR23C1030C patent/FR23C1030I1/fr active Active
- 2023-08-23 LT LTPA2023523C patent/LTPA2023523I1/lt unknown
- 2023-08-28 FI FIC20230028C patent/FIC20230028I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020203967B2 (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
AU2014347275B2 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses | |
AU2013341185B2 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses | |
BR112016010172B1 (pt) | Compostos de piridila substituída por alquil- amida úteis no tratamento de uma doença inflamatória ou autoimune e composição farmacêutica que os compreende |